Evidence map›Paper›PMID 41588416›Full record

ArticleTrials2026

Effectiveness of a CDSS and Internet of Things-based comprehensive hypertension management system in primary health care settings: study protocol for the CATCH Trial.

Bingjie Li, Ke Peng, Ke Xu, Xiaoying Liu, Chenxi Lu, Yu Shi, Guiyuan Han, Liang Wang, Xianrui Chen, Zule Ning and 1 more

Abstract readClinical Trial Protocol
In one paragraph

Article in Trials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bingjie Li *National Clinical Research Center for Cardiovascular Diseases, Heart Failure Ward, Fuwai Hospital Chinese Academy of Medical Sciences, No. 12 Langshan Road, Nanshan District, Shenzhen, Guangdong Province, 518057, People's Republic of China.ORCID http://orcid.org/0009-0000-9618-0525
Ke Peng *National Clinical Research Center for Cardiovascular Diseases, Heart Failure Ward, Fuwai Hospital Chinese Academy of Medical Sciences, No. 12 Langshan Road, Nanshan District, Shenzhen, Guangdong Province, 518057, People's Republic of China.
Ke XuNational Clinical Research Center for Cardiovascular Diseases, Heart Failure Ward, Fuwai Hospital Chinese Academy of Medical Sciences, No. 12 Langshan Road, Nanshan District, Shenzhen, Guangdong Province, 518057, People's Republic of China.
Xiaoying LiuNational Clinical Research Center for Cardiovascular Diseases, Heart Failure Ward, Fuwai Hospital Chinese Academy of Medical Sciences, No. 12 Langshan Road, Nanshan District, Shenzhen, Guangdong Province, 518057, People's Republic of China.
Chenxi LuNational Clinical Research Center for Cardiovascular Diseases, Heart Failure Ward, Fuwai Hospital Chinese Academy of Medical Sciences, No. 12 Langshan Road, Nanshan District, Shenzhen, Guangdong Province, 518057, People's Republic of China.
Yu ShiNational Clinical Research Center for Cardiovascular Diseases, Heart Failure Ward, Fuwai Hospital Chinese Academy of Medical Sciences, No. 12 Langshan Road, Nanshan District, Shenzhen, Guangdong Province, 518057, People's Republic of China.
Guiyuan HanNational Clinical Research Center for Cardiovascular Diseases, Heart Failure Ward, Fuwai Hospital Chinese Academy of Medical Sciences, No. 12 Langshan Road, Nanshan District, Shenzhen, Guangdong Province, 518057, People's Republic of China.
Liang WangNational Clinical Research Center for Cardiovascular Diseases, Heart Failure Ward, Fuwai Hospital Chinese Academy of Medical Sciences, No. 12 Langshan Road, Nanshan District, Shenzhen, Guangdong Province, 518057, People's Republic of China.
Xianrui ChenNational Clinical Research Center for Cardiovascular Diseases, Heart Failure Ward, Fuwai Hospital Chinese Academy of Medical Sciences, No. 12 Langshan Road, Nanshan District, Shenzhen, Guangdong Province, 518057, People's Republic of China.
Zule NingNational Clinical Research Center for Cardiovascular Diseases, Heart Failure Ward, Fuwai Hospital Chinese Academy of Medical Sciences, No. 12 Langshan Road, Nanshan District, Shenzhen, Guangdong Province, 518057, People's Republic of China.
Yichong LiNational Clinical Research Center for Cardiovascular Diseases, Heart Failure Ward, Fuwai Hospital Chinese Academy of Medical Sciences, No. 12 Langshan Road, Nanshan District, Shenzhen, Guangdong Province, 518057, People's Republic of China. yichongli.cvd@139.com.

Funding

National Natural Science Foundation of China No.72404283National Science and Technology Major Project No. 2023ZD0503506Shenzhen Science and Technology Program No. JCYJ2023080715080000Supported by Shenzhen Clinical Research Center for Cardiovascular Diseases Fund No.20220819165348002the Guangdong Basic and Applied Basic Research Foundation NO. 2021A1515220173the Program for Guangdong Introducing Innovative and Enterpreneurial Teams NO. 2019ZT08Y481the Yong Talent Program of the Academician Fund, Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen No.YS-2020-006
6 · The paper itself

Abstract

backgroundCardiovascular and cerebrovascular diseases are the leading causes of death in the Chinese population, and hypertension is one of the key risk factors. However, the blood pressure control rate of hypertensive patients is low at present. The main factors include the limited capacity of primary care workers and poor self-management among hypertensives. The purpose of this program is to use a clinical decision support system (CDSS) and an Internet of Things-based comprehensive hypertension management system (CATCH) to provide decision support for the diagnosis and treatment of hypertension for primary care clinicians and to improve the standardisation of the diagnosis, monitoring, treatment, and continuous management of hypertension among them.

methodsThis study is a stepped wedge cluster randomised controlled trial conducted in 12 community health centres in the Third People's Hospital of Longgang District, Shenzhen City, China. All participants who are registered in the community and with systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg at the screening clinic will be asked to participate in the study. The intervention is a CATCH composite of a hypertension auxiliary decision-making module, clinical diagnosis and treatment knowledge education system, and quality control system. All 12 clusters will be divided into 4 clusters and 5 stages according to a randomised method, with each stage lasting 3 months, ensuring that the entire trial will be completed within 12 months. DISCUSSION: The CATCH trial uses CDSS and IoT to improve hypertension management in primary care. This stepped wedge trial enhances guideline adherence and patient outcomes through remote monitoring and quality control. All centres receive the intervention, ensuring equitable access to it. Results will guide future hypertension strategies.

trial registrationThe trial was registered at the National Medical Research Registration and Record Filing Information System of China in December 2024, was retrospectively registered at the Chinese Clinical Trial Registry (ChiCTR) (Registration number: ChiCTR2500098845) https://www.chictr.org.cn/.

Indexed as

Blood PressureDecision Support Systems, ClinicalHypertensionPrimary Health CareAntihypertensive AgentsChinaDigital HealthHumansInternetMulticenter Studies as TopicRandomized Controlled Trials as TopicTreatment OutcomeAntihypertensive AgentsClinical decision support systemHypertension managementInternet of ThingsRandomised controlled trial

Identifiers

PMID41588416
PMCPMC12918642

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.